--- title: "Knowledge Center - Avance Clinical" canonical: "https://www.avancecro.com/knowledge-center/" generated: "2026-09-20T22:39:15+00:00" --- # **Knowledge Center** [![First-in-Human vs. First-in-Patient: How to Choose](https://www.avancecro.com/wp-content/uploads/2026/09/FIH-FIP-aspect-ratio-40-27-800x540.png)](https://www.avancecro.com/knowledge-center/first-in-human-vs-first-in-patient-how-to-choose/) 4 September 2026 ### [First-in-Human vs. First-in-Patient: How to Choose](https://www.avancecro.com/knowledge-center/first-in-human-vs-first-in-patient-how-to-choose/) The first-in-human vs. first-in-patient decision affects your timeline, data, and your next investor conversation. A drug development expert outlines the study choices. [Read more](https://www.avancecro.com/knowledge-center/first-in-human-vs-first-in-patient-how-to-choose/) [![Enhance Your Recruitment & Retention Strategy For Rare Kidney Disease Trials](https://www.avancecro.com/wp-content/uploads/2026/08/rare-kidney-disease-aspect-ratio-40-27-1000x675.png)](https://www.avancecro.com/knowledge-center/enhance-your-recruitment-retention-strategy-for-rare-kidney-disease-trials/) 21 August 2026 ### [Enhance Your Recruitment & Retention Strategy For Rare Kidney Disease Trials](https://www.avancecro.com/knowledge-center/enhance-your-recruitment-retention-strategy-for-rare-kidney-disease-trials/) Breakthroughs in genetic understanding alongside the growing shift toward accommodating orphan drugs have led to an upswing in clinical trials for rare kidney disease. [Read more](https://www.avancecro.com/knowledge-center/enhance-your-recruitment-retention-strategy-for-rare-kidney-disease-trials/) [![The Rise of Chinese Biotechs and the Global CRO Question](https://www.avancecro.com/wp-content/uploads/2026/08/chinese-biotech-company-aspect-ratio-40-27-1000x675.jpg)](https://www.avancecro.com/knowledge-center/the-rise-of-chinese-biotechs-and-the-global-cro-question/) 6 August 2026 ### [The Rise of Chinese Biotechs and the Global CRO Question](https://www.avancecro.com/knowledge-center/the-rise-of-chinese-biotechs-and-the-global-cro-question/) What's fueling the surge of Chinese biotechs onto the world stage, and what decisions do they face on the path to their first global clinical trial? [Read more](https://www.avancecro.com/knowledge-center/the-rise-of-chinese-biotechs-and-the-global-cro-question/) [![How Australia’s Leading CRO Is Driving Biotech’s Acceleration From First-In-Human To Global Markets](https://www.avancecro.com/wp-content/uploads/2026/05/Mark-Harvill_40-scaled-aspect-ratio-40-27-1200x810.jpg)](https://www.avancecro.com/knowledge-center/how-australias-leading-cro-is-driving-biotechs-acceleration-from-first-in-human-to-global-markets/) 27 May 2026 ### [How Australia’s Leading CRO Is Driving Biotech’s Acceleration From First-In-Human To Global Markets](https://www.avancecro.com/knowledge-center/how-australias-leading-cro-is-driving-biotechs-acceleration-from-first-in-human-to-global-markets/) In 2025, Harvill’s experience overseeing CROs through global expansion across Asia Pacific (APAC), Europe, and South America led him to take the helm at Avance Clinical, Australia’s leading CRO. [Read more](https://www.avancecro.com/knowledge-center/how-australias-leading-cro-is-driving-biotechs-acceleration-from-first-in-human-to-global-markets/) [![CNS Trials Are Difficult — Do They Have To Be?](https://www.avancecro.com/wp-content/uploads/2026/03/CNS-Trials-Are-Difficult-—-Do-They-Have-To-Be-aspect-ratio-40-27.png)](https://www.avancecro.com/knowledge-center/cns-trials-are-difficult-do-they-have-to-be/) 11 March 2026 ### [CNS Trials Are Difficult — Do They Have To Be?](https://www.avancecro.com/knowledge-center/cns-trials-are-difficult-do-they-have-to-be/) Central nervous system (CNS) indications, including mood disorders, neurodegenerative and neurodevelopmental diseases, and chronic pain, affect more than three billion people worldwide and represent the leading cause of illness and disability globally1. [Read more](https://www.avancecro.com/knowledge-center/cns-trials-are-difficult-do-they-have-to-be/) [![Why Early CRO Choice Is Critical To Accelerating Delivery Of Your Clinical Program](https://www.avancecro.com/wp-content/uploads/2026/02/Why-Early-CRO-Choice-Is-Critical-To-Accelerating-Delivery-Of-Your-Clinical-Program-aspect-ratio-40-27.png)](https://www.avancecro.com/knowledge-center/why-early-cro-choice-is-critical-to-accelerating-delivery-of-your-clinical-program/) 11 February 2026 ### [Why Early CRO Choice Is Critical To Accelerating Delivery Of Your Clinical Program](https://www.avancecro.com/knowledge-center/why-early-cro-choice-is-critical-to-accelerating-delivery-of-your-clinical-program/) Australia's pragmatic regulatory environment, accelerated timelines, globally accepted data, Research and Development Tax Incentive, and other advantages, have emerged as a compelling strategy for Phase I trials. [Read more](https://www.avancecro.com/knowledge-center/why-early-cro-choice-is-critical-to-accelerating-delivery-of-your-clinical-program/) [![International Clinical Trials Autumn Issue Is Live](https://www.avancecro.com/wp-content/uploads/2024/05/Jemma-L-2-800x540.jpg)](https://www.avancecro.com/knowledge-center/international-clinical-trials-autumn-issue-is-live/) 20 November 2025 ### [International Clinical Trials Autumn Issue Is Live](https://www.avancecro.com/knowledge-center/international-clinical-trials-autumn-issue-is-live/) The latest International Clinical Trials (ICT) Autumn Issue is now live, featuring an exclusive interview with Jemma Lawson, Avance Clinical’s Executive Vice President, Global Operations. [Read more](https://www.avancecro.com/knowledge-center/international-clinical-trials-autumn-issue-is-live/) [![Cut Timelines and Costs in Late-Phase Oncology: Why Asia Should Be Your Next Trial Destination](https://www.avancecro.com/wp-content/uploads/2025/10/Asia-Oncology-aspect-ratio-40-27-800x540.png)](https://www.avancecro.com/knowledge-center/cut-timelines-and-costs-in-late-phase-oncology-why-asia-should-be-your-next-trial-destination/) 15 October 2025 ### [Cut Timelines and Costs in Late-Phase Oncology: Why Asia Should Be Your Next Trial Destination](https://www.avancecro.com/knowledge-center/cut-timelines-and-costs-in-late-phase-oncology-why-asia-should-be-your-next-trial-destination/) - [Asia Advantage](https://www.avancecro.com/knowledge-center/?_sft_featured_content_category=asia-advantage) Globally, cancer diagnoses are projected to reach 35.3 million new cases per year with death rates rising to 18.5 million by 2050.² [Read more](https://www.avancecro.com/knowledge-center/cut-timelines-and-costs-in-late-phase-oncology-why-asia-should-be-your-next-trial-destination/) [![Unlocking the Potential of FDA Expedited Approval and Voucher Programs: An Avance Clinical Partnership Approach](https://www.avancecro.com/wp-content/uploads/2025/10/FDA-800x540.png)](https://www.avancecro.com/knowledge-center/unlocking-the-potential-of-fda-expedited-approval-and-voucher-programs-an-avance-clinical-partnership-approach/) 15 October 2025 ### [Unlocking the Potential of FDA Expedited Approval and Voucher Programs: An Avance Clinical Partnership Approach](https://www.avancecro.com/knowledge-center/unlocking-the-potential-of-fda-expedited-approval-and-voucher-programs-an-avance-clinical-partnership-approach/) - [North America](https://www.avancecro.com/knowledge-center/?_sft_featured_content_category=north-america) Our integrated approach combines deep regulatory expertise with world-class operational resources to guide Sponsors through every aspect of these complex programs, from initial eligibility assessment to managing post-approval commitments. [Read more](https://www.avancecro.com/knowledge-center/unlocking-the-potential-of-fda-expedited-approval-and-voucher-programs-an-avance-clinical-partnership-approach/) [![Accelerating Development Through Parallel Execution and Rigorous Quality Controls](https://www.avancecro.com/wp-content/uploads/2025/11/Ben-Edwards-2-Pic-49-1-scaled-aspect-ratio-40-27-1200x810.jpg)](https://www.avancecro.com/knowledge-center/accelerating-development-through-parallel-execution-and-rigorous-quality-controls/) 23 September 2025 ### [Accelerating Development Through Parallel Execution and Rigorous Quality Controls](https://www.avancecro.com/knowledge-center/accelerating-development-through-parallel-execution-and-rigorous-quality-controls/) In a recent video interview with Applied Clinical Trials, Ben Edwards, Chief Operating Officer, Avance Clinical, discussed common challenges in biotech, emphasizing the importance of addressing preclinical package gaps to avoid delays. [Read more](https://www.avancecro.com/knowledge-center/accelerating-development-through-parallel-execution-and-rigorous-quality-controls/) [![Advancing Rare Disease Clinical Trials: A High-Touch, Patient-Centered Approach for Biotechs](https://www.avancecro.com/wp-content/uploads/2025/04/Hospital-bed-image-aspect-ratio-40-27-800x540.png)](https://www.avancecro.com/knowledge-center/advancing-rare-disease-clinical-trials-a-high-touch-patient-centered-approach-for-biotechs/) 17 April 2025 ### [Advancing Rare Disease Clinical Trials: A High-Touch, Patient-Centered Approach for Biotechs](https://www.avancecro.com/knowledge-center/advancing-rare-disease-clinical-trials-a-high-touch-patient-centered-approach-for-biotechs/) Avance Clinical supports biotech companies by employing patient-centered trial designs, innovative statistical methodologies, personalized patient support, and expert regulatory guidance. [Read more](https://www.avancecro.com/knowledge-center/advancing-rare-disease-clinical-trials-a-high-touch-patient-centered-approach-for-biotechs/) [![Avance Clinical North America: Proven Expertise With Global Solutions For US Biotechs](https://www.avancecro.com/wp-content/uploads/2025/03/General-USA-aspect-ratio-40-27-800x540.png)](https://www.avancecro.com/knowledge-center/avance-clinical-north-america-proven-expertise-with-global-solutions-for-us-biotechs/) 6 March 2025 ### [Avance Clinical North America: Proven Expertise With Global Solutions For US Biotechs](https://www.avancecro.com/knowledge-center/avance-clinical-north-america-proven-expertise-with-global-solutions-for-us-biotechs/) - [North America](https://www.avancecro.com/knowledge-center/?_sft_featured_content_category=north-america) The success of a biotech drug development program often depends on the relationship it forms with its Clinical Research Organization (CRO) partner. [Read more](https://www.avancecro.com/knowledge-center/avance-clinical-north-america-proven-expertise-with-global-solutions-for-us-biotechs/) **22** results - Page **1** of **2** Page 1 of 21[2](https://www.avancecro.com/knowledge-center/?sf_paged=2) ## Proven industry **experience & expertise** ### 500+ Studies in the past 5 years ### 450+ Experienced team members ### 18k+ Participants past 5 years ### 30 Years of CRO experience [View our capabilities](https://www.avancecro.com/capabilities/our-capabilities/)